Airway Epithelium Gene Expression: AEGIS IDE

Allegro Diagnostics, Corp.1,331 enrolled

Overview

The purpose of the research study is to develop a new, more sensitive, and less invasive test for diagnosing lung cancer at an earlier stage, when it can more easily be cured. The investigators hypothesize that certain genes are expressed differently in current and former smokers who have lung cancer, and this difference in gene expression may be a biomarker for lung cancer.

Allegro Diagnostics is funding this multi-center study to validate and extend a new diagnostic tool measuring global gene expression in airway epithelial cells obtained at routine bronchoscopy in suspect lung cancer patients. The test, which is highly sensitive and specific for lung cancer, measures the levels of expression of genes in cells brushed from the large bronchi during diagnostic bronchoscopy. Similar brushings of epithelial cells from the nose will be analyzed to determine if gene expression in these cells can be used as a screening tool in subjects who may have now or be at risk for developing lung cancer in the future.

Study Type

OBSERVATIONAL

Enrollment

1,331

Conditions

Lung Cancer

Interventions

Biomarker (not used as an intervention)DEVICE

This study is an observational study. There is no intervention.

Eligibility

Sex: ALLMin age: 21 Years

Medical Language ↔ Plain English

Inclusion Criteria: * Patients being evaluated for the diagnosis of possible lung cancer or "rule out lung cancer" and undergoing clinically indicated bronchoscopy * All patients are required to be at least 21 years of age and be able to understand and sign the informed consent form * Patient must be a current or former cigarette smoker Exclusion Criteria: * A pulmonary physician does not recommend that bronchoscopy be performed * Inability to understand the written consent form and comply with requirements of the study * History of prior primary lung cancer * Immediately prior to bronchoscopy, the patient has been on a mechanical ventilator for \>24 consecutive hours.

Locations (21)

University of Alabama

Birmingham, Alabama, United States

Pulmonary Associates of Arizona

Outcomes

Primary Outcomes

Lung Cancer Diagnosis (positive or negative)

Patients may be followed at 12 months post bronchoscopy to finalize diagnosis if diagnosis had not previously been confirmed. The biomarker score will be compared to the standard diagnosis to evaluate the sensitivity, specificity, and negative predictive values of the biomarker.

Time frame: 12 months

Data from ClinicalTrials.gov

This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.